The first outcome-based guidelines for interventional treatment of acute ischemic stroke — providing recommendations for rapid treatment — will benefit individuals suffering from brain attacks, often caused by artery-blocking blood clots. Representatives from the Society of Interventional Radiology (SIR) and seven other medical societies created a multispecialty and international consensus on the metrics and benchmarks for processes of care and technical and clinical outcomes for stroke patients.

PhysioSonics announced the U.S. Food and Drug Administration (FDA) has granted the Presto 1000 Flow Monitor system 510(k) clearance for cranial blood flow monitoring. In addition, the company announced completion of Series B add-on debt financing, closing with $1.05 million.

 

A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain — and can also experience their relief following treatment.


January 31, 2013 — Cardiovascular Systems Inc. (CSI) announced CONFIRM study series data presented at the 2013 International Symposium on Endovascular Therapy (ISET).
ACC AHA Electronic Health Records Clinical Management

The American College of Cardiology (ACC) and the American Heart Association (AHA) released a set of key data elements and definitions for the clinical management of patients with acute coronary syndromes (ACS) and coronary artery disease (CAD). Drafted with the primary goal of aiding data collection, the new standards should ultimately help compare data among different studies, promote the interoperability and applicability of electronic health records (EHRs) and facilitate the adoption of research to clinical practice.

Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS), BioFreedom.

January 31, 2013 — Belgian biotechnology company Cardio3 BioSciences (C3BS) announced it has received authorization to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European phase III trial for C3BS-CQR-1 in Belgium.

Coronary artery disease and peripheral artery disease are global health issues that affect millions of lives each year, and bioabsorbable stents are due to become the next step in treatment once the medical world has provided enough clinical data and prices are lowered, states a new report by research and consulting firm GlobalData.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now